ID

33387

Description

Study ID: 104065 Clinical Study ID: 104065 Study Title: Immune memory of GSK's DTPw-HBV/Hib vaccine by giving Plain PRP polysaccharide at 10 mths. Immuno & reacto of a booster dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 mths in infants previously primed with DTPw-HBV/Hib Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00169442  Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completet Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT) Trade Name: Zilbrix/Hib Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Keywords

  1. 12/7/18 12/7/18 -
Copyright Holder

GSK group of companies

Uploaded on

December 7, 2018

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Immune memory of Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine at infants (15 to 18 mths) - 104065

Contraindications and Elimination Criteria

Administrative data
Description

Administrative data

Subject Number
Description

Subject Number

Data type

integer

Protocol Number
Description

Protocol Number

Data type

integer

Date of Visit
Description

Date of Visit

Data type

date

Elimination Criteria during the Study
Description

Elimination Criteria during the Study

The criteria should be checked at each visit subsequent to the first visit.
Description

If any become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol (ATP) analysis.

Data type

text

Contraindications to Subsequent Vaccination
Description

Contraindications to Subsequent Vaccination

Contraindications to administration of the study vaccines at that point in time
Description

if any one of these AE occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE.

Data type

text

Similar models

Contraindications and Elimination Criteria

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Administrative data
Subject Number
Item
Subject Number
integer
Protocol Number
Item
Protocol Number
integer
Date of Visit
Item
Date of Visit
date
Item Group
Elimination Criteria during the Study
Item
The criteria should be checked at each visit subsequent to the first visit.
text
Code List
The criteria should be checked at each visit subsequent to the first visit.
CL Item
Use of any investigational or non-registered product (drug or vaccine) other that the study vaccine(s) during the study period. (1)
CL Item
Chronic administration (defined as more that 14 days) of immunosuppressants or other immune-modifying drugs during the study period. (For corticosteroids, this will mean prednisone, or equivalent, >=0.5 mg/kg/day. Inhaled and topical steroids are allowed.) (2)
CL Item
Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before administration of the study vaccine and ending 30 days after, with the exception of OPV. (3)
CL Item
Administration of immunoglobulins and/or any blood products during the study period. (4)
Item Group
Contraindications to Subsequent Vaccination
Item
Contraindications to administration of the study vaccines at that point in time
text
Code List
Contraindications to administration of the study vaccines at that point in time
CL Item
Acute disease at the time of vaccination: the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature <37.5°C / rectal temperature <38°C. (1)
CL Item
Axillary temperature >= 37.5°C / rectal temperature >=38°C at the time of booster vaccination. (2)

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial